Antiva Biosciences

Antiva Biosciences is a clinical-stage biopharmaceutical company developing novel topical therapeutics for the treatment of high-risk human papillomavirus (HPV) infections and the pre-cancerous cervical lesions they cause. Founded in 2012 and based in San Francisco, the company aims to provide a non-invasive, self-administered alternative to current surgical procedures. Its mission aligns with global efforts to eliminate cervical cancer by enabling early intervention.